Characteristics and management of patients with stroke and major hemorrhagic episodes with atrial fibrillation under vitamin K antagonist therapy. EVENTHO study

Med Clin (Barc). 2022 Oct 28;159(8):366-371. doi: 10.1016/j.medcli.2021.12.004. Epub 2022 Feb 2.
[Article in English, Spanish]

Abstract

Introduction and objective: In Spain, vitamin K antagonists (VKA) remain the standard treatment for the prevention of thromboembolic and hemorrhagic complications in patients with atrial fibrillation (AF), despite the high risks of suffering adverse effects. The objective of this study was to characterize the profile of VKA-treated patients suffering from stroke/systemic embolism (SE) or major hemorrhagic episodes, their evolution and the actions taken after those episodes.

Materials and methods: EVENTHO was an observational multicenter study conducted in 22 Anticoagulation Spanish Units. The study included patients ≥18 years with AF who suffered major hemorrhagic episodes (67.8%) or stroke/SE (32.1%) during 2016 whileon VKA treatment [acenocoumarol (98.2%) or warfarin (1.8%)]. Time in therapeutic range (TTR) was calculated according to the Rosendaal method based on the international normalized ratio (INR) values of the previous 6 months.

Results: The study included 585 patients (median age [range] 82.3 [43.6-96.2] years; 51.1% men; mean [95% confidence interval, CI] CHA2DS2-VASc: 4.3 [4.2-4.4] and HAS-BLED: 2.2 [2.1-2.3]). Poor anticoagulation and VKA maintenance were higher in patients with major hemorrhagic episode (p<0.0001). The most common situations after hospital discharge were: functional dependence, neurological sequelae and death.

Conclusions: In the sample studied, half of the AF patients who suffered stroke/SE or major hemorrhagic episode had inadequate TTR and, despite this, after hospital discharge, they restarted treatment with VKA. These results highlight the need to evaluate safer and effective therapeutic alternatives in AF patients with poor TTR control after suffering a stroke/SE or major hemorrhagic episode.

Keywords: Alta hospitalaria; Antagonista de la vitamina K; Anticoagulación oral; Atrial fibrillation; Fibrilación auricular; Hospital discharge; Oral anticoagulation; Vitamin K antagonist.

Publication types

  • Multicenter Study

MeSH terms

  • Acenocoumarol / adverse effects
  • Aged, 80 and over
  • Anticoagulants / adverse effects
  • Atrial Fibrillation* / complications
  • Atrial Fibrillation* / drug therapy
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Hemorrhage / chemically induced
  • Hemorrhage / complications
  • Humans
  • International Normalized Ratio / adverse effects
  • Male
  • Stroke* / complications
  • Stroke* / prevention & control
  • Vitamin K
  • Warfarin / adverse effects

Substances

  • Anticoagulants
  • Fibrinolytic Agents
  • Vitamin K
  • Warfarin
  • Acenocoumarol